Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide

Physiol Behav. 2020 Jun 1:220:112870. doi: 10.1016/j.physbeh.2020.112870. Epub 2020 Mar 14.

Abstract

Simultaneously targeting multiple energy balance control systems is a promising direction for the development of obesity pharmacotherapies. Here, we explore the interaction between the GLP-1 and melanocortin system within the dorsal vagal complex (DVC) of the caudal brainstem. Using a pharmacological approach, we demonstrate that the full anorectic potential of liraglutide, an FDA-approved GLP-1 analog for the treatment of obesity, requires DVC melanocortin 3/4 receptor (MC3/4R) signaling. Specifically, the food intake and body weight suppressive effects of liraglutide were attenuated by DVC administration of the MC3/4R antagonist SHU9119. In contrast, the anorectic effects of liraglutide were enhanced by combined activation of DVC MC3/4Rs using the agonist MTII. Our findings highlight the modulation of liraglutide-induced anorexia by DVC MC3/4R signaling, thereby suggesting a site of action at which two important energy balance control systems interact.

Keywords: Area postrema; Brainstem; MSH; NTS; Obesity; POMC.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Body Weight*
  • Eating*
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Liraglutide* / pharmacology
  • Male
  • Melanocortins
  • Rats, Sprague-Dawley
  • Receptor, Melanocortin, Type 3* / metabolism
  • Receptor, Melanocortin, Type 4* / metabolism
  • Receptors, Melanocortin
  • Rhombencephalon / metabolism
  • alpha-MSH / pharmacology

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Melanocortins
  • Receptor, Melanocortin, Type 3
  • Receptor, Melanocortin, Type 4
  • Receptors, Melanocortin
  • alpha-MSH
  • Liraglutide